Specifically, in two (P6, P7) of 10 primary samples, ibrutinib led to reduced viability of more than 50%, triggered considerable upregulation of surface CD52, and rendered the tumor cells more vulnerable to CD52 mAb mediated toxicity, as seen in the ibrutinib-sensitive cell line model. The gene discussed is CD52; the disease is neoplasm.